Roche is trading sharply higher at $55.39 (+4.98%) on September 14, 2026, after collaborator MediLink reported positive interim Phase III TAISHAN-302 results for Tam-Peli in relapsed small-cell lung cancer.
- The treatment reduced death risk by 54%, with median overall survival of 13.3 months versus 9.4 months for topotecan.
- The company-specific catalyst outweighs broader weakness, as major U.S. indices are trading lower.